In analysis of 5268 women from the first childbirth, the proportion of treated women began to decline 18 months before childbirth.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Our findings do not suggest high utilization of neoadjuvant chemotherapy is associated with a trade-off between perioperative and long-term outcomes,” the researchers wrote.

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

Researchers found that an increased risk of long COVID was seen with financial hardship, food insecurity, less than a college education, and lack of social support.